Elsevier

The Lancet

Volume 347, Issue 9013, 25 May 1996, Pages 1438-1442
The Lancet

Articles
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence

https://doi.org/10.1016/S0140-6736(96)91682-7Get rights and content

Abstract

Summary

Background About 50% of alcoholic patients relapse within 3 months of treatment. Previous studies have suggested that acamprosate may help to prevent such relapse. The aim of our study was to assess the efficacy and safety of long-term acamprosate treatment in alcohol dependence.

Methods In this multicentre, double-blind, placebo-controlled study, we recruited 455 patients, aged 18-65 years, with chronic or episodic alcohol dependence. Patients were randomly allocated treatment with acamprosate (1998 mg daily for bodyweight >60 kg; 1332 mg daily for ≤60 kg) or placebo for 360 days. Patients were assessed on the day treatment started and on days 30, 90, 180, 270, and 360 by interview, self-report, questionnaire, and laboratory screening. Patients were classified as abstinent, relapsing, or non-attending. Time to first treatment failure (relapse or non-attendance) was the primary outcome measure.

Findings Seven patients were excluded from the intention-to-treat analysis because they did not attend on the first treatment day and therefore received no medication. The acamprosate (n=224) and placebo (n=224) groups were well matched in terms of baseline demographic and alcohol-related variables. 94 acamprosate-treated and 85 placebo-treated patients completed the treatment phase: of those withdrawn, 104 (52 in each group) relapsed, 69 (33 vs 36, respectively) were lost to follow-up, 63 (31 vs 32) refused to continue treatment, 16 (15 vs 11) had concurrent illness, three (two vs one) died, ten (six vs four) had adverse side-effects, one (acamprosate treated) received the wrong medication, and three (placebo treated) were non-compliant. The proportion without treatment failure was higher in the acamprosate than in the placebo group throughout the treatment period (p<0·001, Mantel-Cox). At the end of treatment, 41 (18·3%) acamprosate-treated and 16 (7·1%) placebo-treated patients had been continuously abstinent (p=0·007). Mean cumulative abstinence duration was significantly greater in the acamprosate group than in the placebo group (138·8 [SD 137·5] vs 103·8 [119·0] days; p=0·012). 148 patients (79 acamprosate, 69 placebo) completed 27 months' follow-up: 27 (11·9%) acamprosate-treated and 11 (4·9%) placebo-treated patients remained continuously abstinent, and the mean cumulative abstinence duration was 230·8 days (259·1) and 183·0 days (235·2), respectively. Apart from occasional diarrhoea, there was no difference in side-effects between groups.

Interpretation Acamprosate is an effective and well-tolerated pharmacological adjunct to psychosocial and behavioural treatment programmes for treatment of alcohol-dependent patients.

References (29)

  • Ca Naranjo et al.

    Possible pharmacological probes for predicting and preventing relapse in treated alcoholics

    Alcohol-Alcohol Suppl

    (1991)
  • Em Sellers et al.

    Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence

    Alcoholism Clin Exp Res

    (1994)
  • Gk Shaw et al.

    Tiapride in the prevention of relapse in recently detoxified alcoholics

    Br J Psychiatry

    (1994)
  • V. Borg

    Bromocriptine in the prevention of alcohol abuse

    Acta Psychiatr Scand

    (1983)
  • Cited by (271)

    • Metabotropic and ionotropic glutamate receptors as potential targets for the treatment of alcohol use disorder

      2017, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Acamprosate is known to affect two neurotransmitter systems, including GABA (as an agonist) and glutamate (as a NMDAR as well as mGluR5 antagonist). The drug was effective in increasing the complete abstinence rate as well as cumulative abstinence duration in several long-term placebo-controlled trials in alcohol-dependent patients (Lhuintre et al., 1990; Paille et al., 1995; Sass et al., 1996; Whitworth et al., 1996). However, in a large clinical trial involving 1383 patients in nine possible treatment groups, acamprosate neither alone nor with naltrexone or combined behavioral intervention shows a statistically significant reduction in alcohol consumption over placebo (Anton et al., 2006).

    View all citing articles on Scopus
    View full text